When paired with anti-PD-L1 antibodies, the combined treatment group demonstrated reduced tumor growth and improved survival relative to controls and each therapy in isolation, as well as lasting immunologic memory that rejected tumor re-challenge [121]. The gene discussed is CD274; the disease is neoplasm.